Stock 2616 CSTONE PHARMACEUTICALS
Add to a list
To use this feature you must be a member
Log inSign up

CStone Pharmaceuticals Stock

Equities

2616

KYG2588M1006

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 EDT 		5-day change 1st Jan Change
0.9 HKD 0.00% Intraday chart for CStone Pharmaceuticals +5.88% -60.35%
04-24 Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5% MT
04-23 CStone Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2024 * 845M 117M 912M 159M Sales 2025 * 978M 135M 1.06B 185M Capitalization 1.06B 146M 1.15B 200M
Net income 2024 * -454M -62.66M -490M -85.66M Net income 2025 * -159M -21.94M -172M -30M EV / Sales 2024 * 0.52 x
Net cash position 2024 * 621M 85.77M 671M 117M Net cash position 2025 * 463M 63.91M 500M 87.37M EV / Sales 2025 * 0.61 x
P/E ratio 2024 *
-2.16 x
P/E ratio 2025 *
-6.17 x
Employees 474
Yield 2024 *
-
Yield 2025 *
-
Free-Float 52.28%
More Fundamentals * Assessed data

Chart CStone Pharmaceuticals

Dynamic Chart

Latest news about CStone Pharmaceuticals

Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5% MT
CStone Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023 CI
China Accepts CStone Pharmaceuticals' Manufacturing Application for RET Inhibitor MT
CStone Announces the Availability of RET Inhibitor GAVRETO® Manufacturing Localization Application by Center for Drug Evalence of China NMPA CI
Cstone Pharmaceuticals Cancer Drug Gets Supplemental Biologics License Application Approved MT
CStone Pharmaceuticals Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer CI
CStone Pharmaceuticals Booted From Hong Kong Stock Connect; Shares Plunge 25% MT
CStone Pharmaceuticals Arm to Sell Ivosidenib Business for $50 Million MT
The Servier Group agreed to acquire CStone Pharmaceuticals, Exclusive rights to TIBSOVO® in Greater China and Singapore from CStone Pharmaceuticals for $44 million. CI
China Includes CStone's Gastrointestinal Stromal Tumor Treatment in National Reimbursement List; Shares Jump 6% MT
China Approves CStone Pharma's Treatment for Esophageal Squamous Cell Carcinoma; Shares Soar 21% MT
CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab as First-Line Treatment for Esophageal Squamous Cell Carcinoma CI
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China MT
CStone Pharmaceuticals Announces Strategic Partnership and Exclusive Licensing Agreement with Shenyang Sunshine Pharmaceuticals Co., Ltd for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China CI
CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3Sbio for Nofazinlimab (ANTI-PD-1 Antibody) in Mainland China CI
More news

Latest transcript on CStone Pharmaceuticals

Logo CStone Pharmaceuticals
CStone Pharmaceuticals, H1 2023 Earnings Call, Aug 16, 2023
More transcripts

Analyst Recommendations on CStone Pharmaceuticals

CStone Pharma's Investigational Antibody Boosts Objective Response Rate of Lymphoma Patients in Clinical Trial MT
CStone Announces Phase 2 GEMSTONE-201 Trial Met Primary Endpoint of Objective Response Rate in Patients with Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL) CI
CStone's Anti-PD-L1 Antibody Demonstrates a Complete Response Rate of 31.8% in Patients With Relapsed or Refractory Extra nodal Natural Killer/T-Cell Lymphoma CI
More recommendations

Press releases CStone Pharmaceuticals

CStone sells to Servier its exclusive rights to TIBSOVO in Greater China and Singapore AQ
CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma AQ
CStone Announces Oral Presentation of Registrational Trial Data from Sugemalimab in First-Line Gastric or Gastroesophageal Junction Adenocarcinoma at ESMO 2023 AQ
CStone Announces NMPA Approval of the AYVAKIT Companion Diagnostic Kit Developed in Partnership with Genetron AQ
CStone Announces Publication of First-in-Human Study Results of Anti-PD-1 Antibody Nofazinlimab in British Journal of Cancer and Update of Global Phase III Trial of Nofazinlimab in HCC AQ
More press releases

News in other languages on CStone Pharmaceuticals

Las acciones chinas suben ante el optimismo en la recuperación y las apuestas a una pausa de la Fed
More news

Quotes and Performance

1 week+5.88%
Current month-4.26%
1 month-5.26%
3 months-49.44%
6 months-50.55%
Current year-60.35%
More quotes

Highs and lows

1 week
0.83
Extreme 0.83
0.93
1 month
0.80
Extreme 0.8
1.03
Current year
0.80
Extreme 0.8
2.38
1 year
0.80
Extreme 0.8
3.40
3 years
0.80
Extreme 0.8
19.12
5 years
0.80
Extreme 0.8
19.12
10 years
0.80
Extreme 0.8
19.12
More quotes

Managers and Directors - CStone Pharmaceuticals

Managers TitleAgeSince
Jian Xin Yang CEO
 Chief Executive Officer 60 16-11-30
Jun Cheng DFI
 Director of Finance/CFO 44 22-02-28
Ying Hua Zhang COO
 Chief Operating Officer 44 16-07-31
Members of the board TitleAgeSince
Edward Hu BRD
 Director/Board Member 61 21-07-08
Wei Li BRD
 Director/Board Member 52 18-09-30
Ting Yuk Wu BRD
 Director/Board Member 69 19-02-13
More insiders

ETFs positioned on CStone Pharmaceuticals

Name Weight AuM 1st Jan change Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
0.75% 4 M€ -27.92%
LEADERSHARES EQUITY SKEW ETF - USD ETF LeaderShares Equity Skew ETF - USD
0.01% 117 M€ +1.11% -
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Emerging Markets Plus Downside Convexity ETF - USD
0.00% 4 M€ -4.41% -
More ETFs positioned on CStone Pharmaceuticals

Quotes

Date Price Change Volume
24-04-26 0.9 0.00% 1,700,000
24-04-25 0.9 -2.17% 624,000
24-04-24 0.92 +6.98% 1,388,000
24-04-23 0.86 +3.61% 650,260
24-04-22 0.83 -2.35% 453,500

Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am

More quotes

Company Profile

CStone Pharmaceuticals is a China-based investment holding company. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The Company conducts its businesses mainly in domestic market.
Sector
Biotechnology & Medical Research
Calendar
2024-08-21 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for CStone Pharmaceuticals

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.8331 CNY
Average target price
3.186 CNY
Spread / Average Target
+282.49%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CSTONE PHARMACEUTICALS Stock CStone Pharmaceuticals
-60.35% 146M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2616 Stock